This MedLibrary.org supplementary page on Antiaggregants is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
It has been suggested that this article or section be merged with antiplatelets. () |
Prevention and treatment of arterial thrombosis
Treatment of established arterial thrombosis includes the use of Antiplatelet drugs and thrombolytic therapy.
Alter the platelet activation at the site of vascular damage crucial to the development of arterial thrombosis.
Aspirin irreversibly inhibits the enzyme COX, resulting in reduced platelet production of TXA2 (thromboxane - powerful vasoconstrictor which lowers cyclic AMP and initiates the platelet release reaction).
Dipyridamole inhibits platelet phosphodiesterase, causing an increase in cyclic AMP with potentiation of the action of PGI2 – opposes actions of TXA2
Clopidogrel affects the ADP-dependent activation of IIb/IIIa complex
Glycoprotein IIb/IIIa receptor antagonists block a receptor on the platelet for fibrinogen and von Willebrand factor. 3 classes:
• Murine-human chimeric antibodies (e.g. abciximab)
• Synthetic peptides (e.g. eptifibatide)
• Synthetic non-peptides (e.g. tirofiban)
Epoprostenol is a prostacyclin which is used to inhibit platelet aggregation during renal dialysis (with or without heparin) and is also used in primary pulmonary hypertension.
'A schematic view[1]of antiaggregants' shows that regulation of platelet aggregation is complex, stepwise, multifactorial and not fully deciphered. Many receptors of aggregation are intertwined. many antagonists exist.
Used in myocardial infarction, cerebral infarction and occasionally in massive pulmonary embolism. The main risk is bleeding. Treatment should not be given to patients who have had recent bleeding, uncontrolled hypertension or a hemorrhagic stroke, or surgery or other invasive procedures within the previous 10 days.
Streptokinase forms a complex with plasminogen, resulting in a conformational change which activates other plasminogen molecules to form plasmin.
Plasminogen activators (PA) Tissue-type plasminogen activators (alteplase, tenecteplase) are produced by recombinant technology.
 |
This article does not cite any references or sources. (January 2008) Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed. |
Wikipedia content modification information:
- This page was last modified on 20 January 2008, at 22:58.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Antiaggregants".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.